Key terms

About IDXX

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest IDXX news

Apr 09 6:20am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX) Feb 26 3:50am ET Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Bausch + Lomb Corporation (BLCO) and Eli Lilly & Co (LLY) Feb 08 7:50am ET Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Neurocrine (NBIX) and Exelixis (EXEL) Feb 08 7:37am ET Idexx Laboratories price target raised to $600 from $525 at Piper Sandler Feb 06 9:19am ET Idexx Laboratories price target raised to $620 from $600 at Morgan Stanley Feb 06 7:26am ET Idexx Laboratories price target raised to $570 from $525 at Stifel Feb 06 5:30am ET Idexx Laboratories price target raised to $655 from $605 at Barclays Feb 05 11:05pm ET Buy Rating Endorsed for Idexx Laboratories Amid Strong Q4 Performance and Promising 2024 Outlook Feb 05 8:31pm ET Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (LLY), Premier (PINC) and Idexx Laboratories (IDXX) Feb 05 9:55am ET Early notable gainers among liquid option names on February 5th Feb 05 6:34am ET Idexx Laboratories sees 2024 EPS $10.84-$11.33, consensus $11.00 Feb 05 6:33am ET Idexx Laboratories reports Q4 EPS $2.32 with items, consensus $2.12 Feb 05 3:10am ET Analysts Conflicted on These Healthcare Names: Roche Holding AG (OtherRHHVF), Eli Lilly & Co (LLY) and Idexx Laboratories (IDXX) Jan 30 4:41am ET Idexx Laboratories downgraded to Neutral from Overweight at Piper Sandler Jan 13 10:02am ET Idexx Laboratories price target raised to $600 from $545 at BofA Jan 13 8:11am ET Analysts Conflicted on These Healthcare Names: UnitedHealth (UNH), Johnson & Johnson (JNJ) and Idexx Laboratories (IDXX) Jan 12 2:18pm ET Idexx Laboratories price target raised to $525 from $440 at Stifel

No recent press releases are available for IDXX

IDXX Financials

1-year income & revenue

Key terms

IDXX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

IDXX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms